Please wait a minute...
Journal of Neurorestoratology  2017, Vol. 5 Issue (1): 39-46    doi: 10.2147/JN.S115756
Expert Opinion     
Clinical cell therapy guidelines for neurorestoration (China version 2016)
Hongyun Huang1, Lin Chen2, Qingyan Zou3, Fabin Han4, Tiansheng Sun5, Gengsheng Mao1, Xijing He6
1 Institute of Neurorestoratology, General Hospital of Armed Police Forces;
2 Department of Neurosurgery, Yuquan Hospital, Tsinghua University, Beijing;
3 Guangdong 999 Brain Hospital, Guangzhou;
4 Centre for Stem Cells and Regenerative Medicine, Affiliated Hospital of Taishan Medical University, Liaocheng, Shandong;
5 Department of Orthopedics, Beijing Army General Hospital, Beijing;
6 Second Department of Orthopedics, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of China
Download: PDF (321 KB)     
Export: BibTeX | EndNote (RIS)      

Abstract  Cell therapy has been shown to be a key clinical therapeutic option for central nervous system disease or damage, and >30 types of cells have been identified through preclinical studies as having the capacity for neurorestoration. To standardize the clinical procedures of cell therapy as one of the strategies for treating neurological disorders, the first set of guidelines governing the clinical application of neurorestoration was completed in 2011 by the Chinese Branch of the International Association of Neurorestoratology. Given the rapidly advancing state of the field, the Neurorestoratology Professional Committee of Chinese Medical Doctor Association (Chinese Association of Neurorestoratology) and the Chinese Branch of the International Association of Neurorestoratology have approved the current version known as the “Clinical Cell Therapy Guidelines for Neurorestoration (China Version 2016)”. We hope this guideline will reflect the most recent results demonstrated in preclinical research, transnational studies, and evidence-based clinical studies, as well as guide clinical practice in applying cell therapy for neurorestoration.

Key wordscell therapy      neurorestoration      China      clinical application     
Received: 25 June 2016      Published: 26 December 2017
Corresponding Authors: Xijing He, Second Department of Orthopedics, The Second Affiliated Hospital of Xi’an Jiaotong University, 157 West Road, 710004 Xi’an, Shaanxi, People’s Republic of China Tel +86 139 0926 6195 Email; Hongyun Huang, Institute of Neurorestoratology, General Hospital of Armed Police Forces, 100039 Beijing, People’s Republic of China Tel +86 139 1011 6608 Email   
Cite this article:

Hongyun Huang, Lin Chen, Qingyan Zou, Fabin Han, Tiansheng Sun, Gengsheng Mao, Xijing He. Clinical cell therapy guidelines for neurorestoration (China version 2016). Journal of Neurorestoratology, 2017, 5: 39-46.

URL:     OR

1. Young W, AlZoubi Z, Saberi H, et al. Beijing declaration of international association of neurorestoratology (IANR).J Neurorestoratol. 2015;3:121-122.
2. Döbrössy M, Busse M, Piroth T, Rosser A, Dunnett S, Nikkhah G.Neurorehabilitation with neural transplantation.Neurorehabil Neural Repair. 2010;24(8):692-701.
3. Ghanizadeh A.Non-neuronal cell transplantation as a possible therapeutic approach for epilepsy treatment.Brain Res Bull. 2010;83(5):194-195.
4. Waldau B, Hattiangady B, Kuruba R, Shetty AK.Medial ganglionic eminence-derived neural stem cell grafts ease spontaneous seizures and restore GDNF expression in a rat model of chronic temporal lobe epilepsy.Stem Cells. 2010;28(7):1153-1164.
5. Huang H, Chen L, Sanberg P.Cell therapy from bench to bedside translation in CNS neurorestoratology era.Cell Med. Part B Cell Transplant. 2010;1(1):15-46.
6. Choi JH, Chung JY, Yoo DY, et al.Cell proliferation and neuroblast differentiation in the rat dentate gyrus after intrathecal treatment with adipose-derived mesenchymal stem cells.Cell Mol Neurobiol. 2011;31(8):1271-1280.
7. Lopatina T, Kalinina N, Karagyaur M, et al.Adipose-derived stem cells stimulate regeneration of peripheral nerves: BDNF secreted by these cells promotes nerve healing and axon growth de novo.PLoS One. 2011;6(3):e17899.
8. Ikegame Y, Yamashita K, Hayashi S, et al.Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy.Cytotherapy. 2011;13(6):675-685.
9. Yang YC, Liu BS, Shen CC, Lin CH, Chiao MT, Cheng HC.Transplantation of adipose tissue-derived stem cells for treatment of focal cerebral ischemia.Curr Neurovasc Res. 2011;8(1):1-13.
10. Yalvac ME, Rizvanov AA, Kilic E, et al.Potential role of dental stem cells in the cellular therapy of cerebral ischemia.Curr Pharm Des. 2009;15(33):3908-3916.
11. Dell’Anno MT, Caiazzo M, Leo D, et al. Remote control of induced dopaminergic neurons in parkinsonian rats.J Clin Invest. 2014;124(7):3215-3229.
12. Dyson SC, Barker RA.Cell-based therapies for Parkinson’s disease.Expert Rev Neurother. 2011;11(6):831-844.
13. Lasala GP, Minguell JJ.Vascular disease and stem cell therapies.Br Med Bull. 2011;98:187-197.
14. Rhee YH, Ko JY, Chang MY, et al.Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease.J Clin Invest. 2011;121(6):2326-2335.
15. Hunt CJ.Cryopreservation of human stem cells for clinical application: a review.Transfus Med Hemother. 2011;38(2):107-123.
16. Zhang Y, Wang D, Chen M, Yang B, Zhang F, Cao K.Intramyocardial transplantation of undifferentiated rat induced pluripotent stem cells causes tumorigenesis in the heart.PLoS One. 2011;6(4):e19012.
17. Tomaskovic-Crook E, Crook JM.Human embryonic stem cell therapies for neurodegenerative diseases.CNS Neurol Disord Drug Targets. 2011;10(4):440-448.
18. Hernándeza J, Torres-Espína A, Navarro X.Adult stem cell transplants for spinal cord injury repair: current state in preclinical research.Curr Stem Cell Res Ther. 2011;6(3):273-287.
19. Loewenbrück K, Storch A.Stem cell-based therapies in Parkinson’s disease: future hope or current treatment option?J Neurol. 2011;258(suppl 2):S346-S353.
20. Lunn JS, Sakowski SA, Federici T, Glass JD, Boulis NM, Feldman EL.Stem cell technology for the study and treatment of motor neuron diseases.Regen Med. 2011;6(2):201-213.
21. Hilfiker A, Kasper C, Hass R, Haverich A.Mesenchymal stem cells and progenitor cells in connective tissue engineering and regenerative medicine: is there a future for transplantation?Langenbecks Arch Surg. 2011;396(4):489-497.
22. Gaspard N, Vanderhaeghen P.From stem cells to neural networks: recent advances and perspectives for neurodevelopmental disorders.Dev Med Child Neurol. 2011;53(1):13-17.
23. Pellegrini KL, Beilharz MW.The survival of myoblasts after intramuscular transplantation is improved when fewer cells are injected.Transplantation. 2011;91(5):522-526.
24. Chang YK, Chen MH, Chiang YH, et al.Mesenchymal stem cell transplantation ameliorates motor function deterioration of spinocerebellar ataxia by rescuing cerebellar Purkinje cells.J Biomed Sci. 2011;18(1):54.
25. Yalvaç ME, Yarat A, Mercan D, Rizvanov AA, Palotás A,Şahin F. Characterization of the secretome of human tooth germ stem cells (hTGSCs) reveals neuro-protection by fine-tuning micro-environment. Brain Behav Immun. 2013;32:122-130.
26. Amoh Y, Li L, Katsuoka K, Hoffman RM.Multipotent hair follicle stem cells promote repair of spinal cord injury and recovery of walking function.Cell Cycle. 2008;7(12):1865-1869.
27. Lee JM, Bae JS, Jin HK.Intracerebellar transplantation of neural stem cells into mice with neurodegeneration improves neuronal networks with functional synaptic transmission.J Vet Med Sci. 2010;72(8):999-1009.
28. Sotelo C, Alvarado-Mallart RM.Reconstruction of the defective cerebellar circuitry in adult Purkinje cell degeneration mutant mice by Purkinje cell replacement through transplantation of solid embryonic implants.Neuroscience. 1987;20(1):1-22.
29. Novikova LN, Lobov S, Wiberg M, Novikov LN.Efficacy of olfactory ensheathing cells to support regeneration after spinal cord injury is influenced by method of culture preparation.Exp Neurol. 2011;229(1):132-142.
30. Su L, Xu J, Ji BX, et al.Autologous peripheral blood stem cell transplantation for severe multiple sclerosis.Int J Hematol. 2006;84(3):276-281.
31. Yarygin KN, Kholodenko IV, Konieva AA, et al.Mechanisms of positive effects of transplantation of human placental mesenchymal stem cells on recovery of rats after experimental ischemic stroke.Bull Exp Biol Med. 2009;148(6):862-868.
32. Loftis JM.Sertoli cell therapy: a novel possible treatment strategy for treatment-resistant major depressive disorder.Med Hypotheses. 2011;77(1):35-42.
33. Caiazzo M, Dell’anno MT, Dvoretskova E, et al.Direct generation of functional dopaminergic neurons from mouse and human fibroblasts.Nature. 2011;476(7359):224-227.
34. Xu X, Geremia N, Bao F, Pniak A, Rossoni M, Brown A.Schwann cell co-culture improves the therapeutic effect of bone marrow stromal cells on recovery in spinal cord-injured mice.Cell Transplant. 2010;20(7):1065-1086.
35. Schwartz M.“Tissue-repairing” blood-derived macrophages are essential for healing of the injured spinal cord: from skin-activated macrophages to infiltrating blood-derived cells?Brain Behav Immun. 2010;24(7):1054-1057.
36. Vaquero J, Zurita M.Functional recovery after severe CNS trauma: current perspectives for cell therapy with bone marrow stromal cells.Prog Neurobiol. 2010;93(3):341-349.
37. Roshal LM, Tzyb AF, Pavlova LN, et al.Effect of cell therapy on recovery of cognitive functions in rats during the delayed period after brain injury.Bull Exp Biol Med. 2009;148(1):140-147.
38. Lin YC, Ko TL, Shih YH, et al.Human umbilical mesenchymal stem cells promote recovery after ischemic stroke.Stroke. 2011;42(7):2045-2053.
39. Chehrehasa F, Windus LC, Ekberg JA, et al.Olfactory glia enhance neonatal axon regeneration.Mol Cell Neurosci. 2010;45(3):277-288.
40. Bonner JF, Connors TM, Silverman WF, Kowalski DP, Lemay MA, Fischer I.Grafted neural progenitors integrate and restore synaptic connectivity across the injured spinal cord.J Neurosci. 2011;31(12):4675-4686.
41. Nagai N, Kawao N, Okada K, et al.Systemic transplantation of embryonic stem cells accelerates brain lesion decrease and angiogenesis.Neuroreport. 2010;21(8):575-579.
42. Ronaghi M, Erceg S, Moreno-Manzano V, Stojkovic M.Challenges of stem cell therapy for spinal cord injury: human embryonic stem cells, endogenous neural stem cells, or induced pluripotent stem cells?Stem Cells. 2010;28(1):93-99.
43. Salehi M, Pasbakhsh P, Soleimani M, et al.Repair of spinal cord injury by co-transplantation of embryonic stem cell-derived motor neuron and olfactory ensheathing cell.Iran Biomed J. 2009;13(3):125-135.
44. Park BW, Kang DH, Kang EJ, et al.Peripheral nerve regeneration using autologous porcine skin-derived mesenchymal stem cells.J Tissue Eng Regen Med. 2012;6(2):113-124.
45. Rosenkranz K, Meier C.Umbilical cord blood cell transplantation after brain ischemia-From recovery of function to cellular mechanisms.Ann Anat. 2011;193(4):371-379.
46. Xiong N, Cao X, Zhang Z, et al.Long-term efficacy and safety of human umbilical cord mesenchymal stromal cells in rotenone-induced hemiparkinsonian rats.J Tissue Eng Regen Med. 2012;6(2):113-124.
47. Dongmei H, Jing L, Mei X, et al.Clinical analysis of the treatment of spinocerebellar ataxia and multiple system atrophy-cerebellar type with umbilical cord mesenchymal stromal cells.Cytotherapy. 2011;13(8):913-917.
48. Wang Y, Piao JH, Larsen EC, Kondo Y, Duncan ID.Migration and remyelination by oligodendrocyte progenitor cells transplanted adjacent to focal areas of spinal cord inflammation.J Neurosci Res. 2011;89(11):1737-1746.
49. Xu XX, Shao XM, Yu F, Liu LM, Zhang MX, Gao XL.Effects of tanycytes transplantation on the motor function score and rubrospinal motor evoked potentials of adult rats after spinal cord completely transected.Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2010;26(4):433-435.
50. Michel-Monigadon D, Brachet P, Neveu I, Naveilhan P.Immunoregulatory properties of neural stem cells.Immunotherapy. 2011;3(4 suppl):39-41.
51. Obenaus A, Dilmac N, Tone B, et al.Long-term magnetic resonance imaging of stem cells in neonatal ischemic injury.Ann Neurol. 2011;69(2):282-291.
52. Eaton MJ, Widerström-Noga E, Wolfe SQ.Subarachnoid transplant of the human neuronal hNT2.19 serotonergic cell line attenuates behavioral hypersensitivity without affecting motor dysfunction after severe contusive spinal cord injury.Neurol Res Int. 2011;2011:891605.
53. Minnerup J, Kim JB, Schmidt A, et al.Effects of neural progenitor cells on sensorimotor recovery and endogenous repair mechanisms after photothrombotic stroke.Stroke. 2011;42(6):1757-1763.
54. Wang R, Zhang J, Guo Z, et al.In-vivo PET imaging of implanted human retinal pigment epithelium cells in a Parkinson’s disease rat model.Nucl Med Commun. 2008;29(5):455-461.
55. Narantuya D, Nagai A, Sheikh AM, et al.Microglia transplantation attenuates white matter injury in rat chronic ischemia model via matrix metalloproteinase-2 inhibition.Brain Res. 2010;1316:145-152.
56. Davies SJ, Shih CH, Noble M, Mayer-Proschel M, Davies JE, Proschel C.Transplantation of specific human astrocytes promotes functional recovery after spinal cord injury.PLoS One. 2011;6(3):e17328.
57. Yang X, Song L, Wu N, Liu Z, Xue S, Hui G.An experimental study on intracerebroventricular transplantation of human amniotic epithelial cells in a rat model of Parkinson’s disease.Neurol Res. 2010;32(10):1054-1059.
58. Cipriani S, Bonini D, Marchina E, et al.Mesenchymal cells from human amniotic fluid survive and migrate after transplantation into adult rat brain.Cell Biol Int. 2007;31(8):845-850.
59. Huang H, Chen L.Questions and discussion of clinical cell therapy in neurorestoratology.Chin J Cell Stem Cell. 2012;2:154-159.
60. Huang H, Mao G, Chen L, Liu A.Progress and challenges with clinical cell therapy in neurorestoratology.J Neurorestoratol. 2015;3:91-95.
61. Buzanska L, Jurga M, Stachowiak EK, Stachowiak MK, Domanska-Janik K.Neural stem-like cell line derived from a nonhematopoietic population of human umbilical cord blood.Stem Cells Dev. 2006;15(3):391-406.
62. Janowski M, Lukomska B, Domanska-Janik K.Migratory capabilities of human umbilical cord blood-derived neural stem cells (HUCB-NSC) in vitro.Acta Neurobiol Exp. 2011;71(1):24-35.
63. Vertès A.2010 world stem cell summit - part 2.IDrugs. 2010;13(12):822-824.
64. Schwarz SC, Schwarz J.Translation of stem cell therapy for neurological diseases.Transl Res. 2010;156(3):155-160.
65. Baker M.Stem-cell pioneer bows out.Nature. 2011;479(7374):459.
66. Reardon S, Cyranoski D.Japan stem-cell trial stirs envy.Nature. 2014;513(7518):287-288.
67. Brown SA, Levi B, Lequeux C, Wong VW, Mojallal A, Longaker MT.Basic science review on adipose tissue for clinicians.Plast Reconstr Surg. 2010;126(6):1936-1946.
68. Huang HY, Chen L, Wang HM, et al.Influence of patients’ age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury.Chin Med J. 2003;116(10):1488-1491.
69. Huang H, Chen L, Xi H, et al.Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study.Clin Transplant. 2008;22(6):710-718.
70. Raisman G, Carlstedt T, Choi D, Li Y.Clinical prospects for transplantation of OECs in the repair of brachial and lumbosacral plexus injuries: opening a door.Exp Neurol. 2011;229(1):168-173.
71. Lima C, Escada P, Pratas-Vital J, et al.Olfactory mucosal autografts and rehabilitation for chronic traumatic spinal cord injury.Neurorehabil Neural Repair. 2010;24(1):10-22.
72. Mackay-Sim A, Féron F, Cochrane J, et al.Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3-year clinical trial.Brain. 2008;131(pt 9):2376-2386.
73. Chen L, Huang H, Xi H, et al.Intracranial transplant of olfactory ensheathing cells in children and adolescents with cerebral palsy: a randomized controlled clinical trial.Cell Transplant. 2010;19(2):185-191.
74. Mizuno H.Adipose-derived stem and stromal cells for cell-based therapy: current status of preclinical studies and clinical trials.Curr Opin Mol Ther. 2010;12(4):442-449.
75. Sanberg PR, Eve DJ, Willing AE, et al.The treatment of neurodegenerative disorders using umbilical cord blood and menstrual blood-derived stem cells.Cell Transplant. 2011;20(1):85-94.
76. Richardson RM, Freed CR, Shimamoto SA, Starr PA.Pallidal neuronal discharge in Parkinson’s disease following intraputamenal fetal mesencephalic allograft.J Neurol Neurosurg Psychiatry. 2011;82(3):266-271.
77. Mendez I, Dagher A, Hong M, et al.Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases.J Neurosurg. 2002;96(3):589-596.
78. Liao GP, Harting MT, Hetz RA, et al.Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children.Pediatr Crit Care Med. 2015;16(3):245-255.
79. Walker PA, Harting MT, Shah SK, et al.Progenitor cell therapy for the treatment of central nervous system injury: a review of the state of current clinical trials.Stem Cells Int. 2010;2010:369578.
80. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al.Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.Arch Neurol. 2010;67(10):1187-1194.
81. Attar A, Ayten M, Ozdemir M, et al.An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells.Cytotherapy. 2011;13(1):54-60.
82. Freedman MS, Bar-Or A, Atkins HL, et al.The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.Mult Scler. 2010;16(4):503-510.
83. Forthofer M, Wirth ED 3rd. Coordination of a neural tissue transplantation study in patients with posttraumatic syringomyelia.SCI Nurs. 2001;18(1):19-29.
84. Yang WZ, Zhang Y, Wu F, et al.Human umbilical cord blood-derived mononuclear cell transplantation: case series of 30 subjects with hereditary ataxia.J Transl Med. 2011;9:65.
85. López-Lozano JJ, Bravo G, Brera B, et al.Long-term follow-up in 10 Parkinson’s disease patients subjected to fetal brain grafting into a cavity in the caudate nucleus: the Clinica Puerta de Hierro experience. CPH Neural Transplantation Group.Transplant Proc. 1995;27(1):1395-1400.
86. Appel SH, Engelhardt JI, Henkel JS, et al.Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis.Neurology. 2008;71(17):1326-1334.
87. Sharma A, Gokulchandran N, Sane H, et al.Detailed analysis of the clinical effects of cell therapy for thoracolumbar spinal cord injury: an original study.J Neurorestoratol. 2013;1:13-22.
88. Gong D, Yu H, Wang W, Yang H, Han F.Human umbilical cord blood mononuclear cell transplantation for delayed encephalopathy after carbon monoxide intoxication.J Neurorestoratol. 2013;1:23-29.
89. Sych N, Klunnik M, Ivankova O, et al.Efficacy of fetal stem cells in Duchenne muscular dystrophy therapy.J Neurorestoratol. 2014;2:37-46.
90. Tsolaki M, Zygouris S, Tsoutsikas V, Anestakis D, Koliakos G.Treatment with adipose stem cells in a patient with moderate Alzheimer’s disease: case report.J Neurorestoratol. 2015;3:115-120.
91. Huang H, Sun T, Chen L, et al.Consensus of clinical neurorestorative progress in patients with complete chronic spinal cord injury.Cell Transplant. 2014;23(suppl 1):S5-S17.
92. Qiao L, Huang H, Muresanu DF.Clinical neurorestorative progress in Alzheimer’s disease.J Neurorestoratol. 2015;3:1-9.
93. Huang H, Chen L, Huang H.Clinical neurorestorative progress in traumatic brain injury.J Neurorestoratol. 2015;3:57-62.
94. Qiao L, Lu J, Huang H.Clinical neurorestorative progress in stroke.J Neurorestoratol. 2015;3:63-71.
95. Geng TC, Mark VW.Clinical neurorestorative progress in multiple sclerosis.J Neurorestoratol. 2015;3:83-90.
96. Chen L, Huang H, Duan WM, Mao GS.Clinical neurorestorative progress in Parkinson’s disease.J Neurorestoratol. 2015;3:101-107.
97. Chen L, Huang H, Xi H, Mao G.Clinical neurorestorative progress in amyotrophic lateral sclerosis.J Neurorestoratol. 2015;3:109-114.
98. Moviglia GA, Varela G, Brizuela JA, et al.Case report on the clinical results of a combined cellular therapy for chronic spinal cord injured patients.Spinal Cord. 2009;47(6):499-503.
99. Moviglia GA, Moviglia-Brandolino MT, Varela GS, et al.Feasibility, safety, and preliminary proof of principles of autologous neural stem cell treatment combined with T-cell vaccination for ALS patients.Cell Transplant. 2012;21(suppl 1):S57-S63.
100. Huang H, Xi H, Chen L, Zhang F, Liu Y.Long-term outcome of olfactory ensheathing cell therapy for patients with complete chronic spinal cord injury.Cell Transplant. 2012;21(suppl 1):S23-S31.
101. Tabakow P, Jarmundowicz W, Czapiga B, et al.Transplantation of autologous olfactory ensheathing cells in complete human spinal cord injury.Cell Transplant. 2013;22(9):1591-1612.
102. Tabakow P, Raisman G, Fortuna W, et al.Functional regeneration of supraspinal connections in a patient with transected spinal cord following transplantation of bulbar olfactory ensheathing cells with peripheral nerve bridging.Cell Transplant. 2014;23(12):1631-1655.
103. Riley J, Glass J, Feldman EL, et al.Intraspinal stem cell transplantation in ALS: a phase I trial, cervical microinjection and final surgical safety outcomes.Neurosurgery. 2012;71(2):405-416.
104. Feldman EL, Boulis NM, Hur J, et al.Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes.Ann Neurol. 2014;75(3):363-373.
105. Mazzini L, Ferrero I, Luparello V, et al.Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial.Exp Neurol. 2010;223(1):229-237.
106. Mazzini L, Gelati M, Profico DC, et al.Human neural stem cell transplantation in ALS: initial results from a phase I trial.J Transl Med. 2015;13:17.
107. Seledtsova GV, Rabinovich SS, Belogorodtsev SN, Parlyuk OV, Seledtsov VI, Kozlov VA.Delayed results of transplantation of fetal neurogenic tissue in patients with consequences of spinal cord trauma.Bull Exp Biol Med. 2010;149(4):530-533.
108. Chinese Branch of International Association of Neurrestoratology & Preparatory Committee of Chinese Association of Neurrestoratology. Chinese clinical standard of neurorestorative cell therapy (2011 first vision).Chin J Clin Phys. 2011;5(19):5710-5714.
109. Chinese Branch of the International Association of Neurorestoratology; Preparatory Committee of Chinese Association of Neurorestoratology. Standard recommendation for the application of Chinese clinical cell therapy for neurorestoration.Cell Transplant. 2013;22(S1):S5-S10.
110. Chinese Association of Neurorestoratology & Chinese Branch of International Association of Neurrestoratology. Clinical application guideline of neurorestorative cell therapy in China (2016 version).Chin J Cell Stem Cell. 2016;6:1-7.
111. Gobbel GT, Kondziolka D, Fellows-Mayle W, Uram M.Cellular transplantation for the nervous system: impact of time after preparation on cell viability and survival.J Neurosurg. 2010;113(3):666-672.
112. Savitz SI, Dinsmore J, Wu J, Henderson GV, Stieg P, Caplan LR.Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study.Cerebrovasc Dis. 2005;20(2):101-107.
113. Nelson PT, Kondziolka D, Wechsler L, et al.Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantation.Am J Pathol. 2002;160(4):1201-1206.
114 114. Huang H, Chen L, Xi H, et al. [Olfactory ensheathing cells transplantation for central nervous system diseases in 1,255 patients]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi.2009;23(1):14-20. Chinese.
115. Lim JH, Byeon YE, Ryu HH, et al.Transplantation of canine umbilical cord blood-derived mesenchymal stem cells in experimentally induced spinal cord injured dogs.J Vet Sci. 2007;8(3):275-282.
116. Mehta T, Feroz A, Thakkar U, Vanikar A, Shah V, Trivedi H.Subarachnoid placement of stem cells in neurological disorders.Transplant Proc. 2008;40(4):1145-1147.
117. Attistella V, de Freitas GR, da Fonseca LM, et al. Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke.Regen Med. 2011;6(1):45-52.
118. Friedrich MA, Martins MP, Araujo MD, et al.Intra-arterial infusion of autologous bone marrow mononuclear cells in patients with moderate to severe middle cerebral artery acute ischemic stroke.Cell Transplant. 2012;21(suppl 1):S13-S21.
119. Moviglia GA, Fernandez Vina R, Brizuela JA, et al.Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients.Cytotherapy. 2006;8(3):202-209.
120. Lee JS, Hong JM, Moon GJ, et al.A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke.Stem Cells. 2010;28(6):1099-1106.
121. Bang OY, Lee JS, Lee PH, Lee G.Autologous mesenchymal stem cell transplantation in stroke patients.Ann Neurol. 2005;57(6):874-882.
122. Lin C, Huang HY, Zhao J, et al.Electromyogram evaluation in 389 patients with amyotrophic lateral sclerosis following olfactory ensheathing cell intracranial transplantation.J Clin Rehabil Tissue Eng Res. 2008;12(43):8422-8425.
123 123. Luan Z, Liu WP, Qu SQ, et al. [Treatment of newborns with severe injured brain with transplantation of human neural precursor cells]. Zhonghua Er Ke Za Zhi.2011;49(6):445-449. Chinese.
124. Chen L,tXi H, Huang H, et al. Multiple cell transplantation based on an intraparenchymal approach for patients with chronic phase stroke.Cell Transplant. 2013;22(suppl 1):S83-S91.
125. Xi H, Chen L, Huang H, et al.Preliminary report of multiple cell therapy for patients with multiple system atrophy.Cell Transplant. 2013;22(suppl1):S93-S99.
126. Chen L, Huang H, Xi H, et al.A prospective randomized double-blind clinical trial using a combination of olfactory ensheathing cells and Schwann cells for the treatment of chronic complete spinal cord injuries.Cell Transplant. 2014;23(suppl 1):S35-S44.
127. Wang S, Cheng H, Dai G, et al.Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury.Brain Res. 2013;1532:76-84.
128. Li JF, Zhang DJ, Geng T, et al.The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis.Cell Transplant. 2014;23(suppl 1):S113-S122.
129. Wang X, Hu H, Hua R, et al.Effect of umbilical cord mesenchymal stromal cells on motor functions of identical twins with cerebral palsy: pilot study on the correlation of efficacy and hereditary factors.Cytotherapy. 2015;17(2):224-231.
130. Li P, Cui K, Zhang B, et al.Transplantation of human umbilical cord-derived mesenchymal stems cells for the treatment of Becker muscular dystrophy in affected pedigree members.Int J Mol Med. 2015;35(4):1051-1057.
131. Chen L, Chen D, Xi H, et al.Olfactory ensheathing cell neurorestorotherapy for amyotrophic lateral sclerosis patients: benefits from multiple transplantations.Cell Transplant. 2012;21(suppl 1):S65-S77.
132. Li Y, Chen L, Zhao Y, et al.Intracranial transplant of olfactory ensheathing cells can protect both upper and lower motor neurons in amyotrophic lateral sclerosis.Cell Transplant. 2013;22(suppl 1):S51-S65.
133. Huang H, Raisman G, Sanberg PR, Sharma H, Chen L.Neurorestoratology. New York: Nova Biomedical; 2015:93-102.
134. Huang H. CNS Neurorestoratology.Beijing: Science Press; 2009.
[1] Xiaoling Guo, Qun Xue, Jianhua Zhao, Yi Yang, Yang Yu, Dezhong Liu, Jing Liu, Wenwu Yang, Linsen Mu, Ping Zhang, Tianyi Wang, Hongyan Han, Shoufeng Liu, Yuhua Zhu, Tao Wang, Chuanqiang Qu, Chuanqiang Qu. Clinical diagnostic and therapeutic guidelines of stroke neurorestoration (2020 China version)[J]. Journal of Neurorestoratology, 2020, 8(4): 241-251.
[2] Hongyun Huang, Wenyong Gao, Zhenghui Yan, Aibing Liu, Xijing He, Ming Lu, Ying Liu, Yixin Shen, Jianhua Zhao, Zuncheng Zheng, Tiansheng Sun, Yaojian Rao, Yaojian Rao. Standards of clinical-grade olfactory ensheathing cell culture and quality control (2020 China Version)[J]. Journal of Neurorestoratology, 2020, 8(4): 217-231.
[3] Yunliang Wang, Xiaoling Guo, Jun Liu, Zuncheng Zheng, Ying Liu, Wenyong Gao, Juan Xiao, Yanqiu Liu, Yan Li, Manli Tang, Linlin Wang, Lin Chen, Di Chen, Deqiang Guo, Fei Liu, Weidong Chen, Baomin Chan, Bo Zhou, Aibing Liu, Gengsheng Mao, Hongyun Huang. Olfactory ensheathing cells in chronic ischemic stroke: A phase 2, double-blind, randomized, controlled trial[J]. Journal of Neurorestoratology, 2020, 8(3): 182-193.
[4] Xinyu Wang, Nan Sun, Xiangqi Meng, Meng Chen, Chuanlu Jiang, Jinquan Cai. Review of clinical nerve repair strategies for neurorestoration of central nervous system tumor damage[J]. Journal of Neurorestoratology, 2020, 8(3): 172-181.
[5] Hongyun Huang, Lin Chen, Gengsheng Mao, Hari Shanker Sharma. Clinical neurorestorative cell therapies: Developmental process, current state and future prospective[J]. Journal of Neurorestoratology, 2020, 8(2): 61-82.
[6] Xiaoling Guo, Xin Wang, Yan Li, Bo Zhou, Weidong Chen, Lihua Ren. Olfactory ensheathing cell transplantation improving cerebral infarction sequela: a case report and literature review[J]. Journal of Neurorestoratology, 2019, 7(2): 82-88.
[7] Gengsheng Mao, Yunliang Wang, Xiaoling Guo, Jun Liu, Zuncheng Zheng, Lin Chen. Neurorestorative effect of olfactory ensheathing cells and Schwann cells by intranasal delivery for patients with ischemic stroke: design of a multicenter randomized double-blinded placebo-controlled clinical study[J]. Journal of Neurorestoratology, 2018, 6(1): 74-80.
[8] Zhongju Shi, Zhijian Wei, Shiqing Feng, Gustavo Moviglia, Lin Chen, Ping Wu. Highlights for the 10th Annual Conference of the International Association of Neurorestoratology[J]. Journal of Neurorestoratology, 2018, 6(1): 84-87.
[9] Andrey S. Bryukhovetskiy. Translational experience of 28 years of use of the technologies of regenerative medicine to treat complex consequences of the brain and spinal cord trauma: Results, problems and conclusions[J]. Journal of Neurorestoratology, 2018, 6(1): 99-114.
[10] Lin Chen, Yuqi Zhang, Xijing He, Saberi Hooshang. Comparison of intramedullary transplantation of olfactory ensheathing cell for patients with chronic complete spinal cord injury worldwide[J]. Journal of Neurorestoratology, 2018, 6(1): 146-151.
[11] Hongyun Huang, Hari Shanker Sharma, Lin Chen, Ali Otom, Ziad M. Al Zoubi, Hooshang Saberi, Dafin F. Muresanu, Xijing He. Review of clinical neurorestorative strategies for spinal cord injury: Exploring history and latest progresses[J]. Journal of Neurorestoratology, 2018, 6(1): 171-178.
[12] Juan Xiao, Lin Chen, Gengsheng Mao, Wenyong Gao, Ming Lu, Xijing He, Hongyun Huang. Neurorestorative clinical application standards for the culture and quality control of olfactory ensheathing cells[J]. Journal of Neurorestoratology, 2017, 5(1): 175-179.
[13] Feng Zhang, Xiangzhi Meng, Fang Lu, Aixian Liu, Hongyun Huang. Olfactory ensheathing cell transplantation for a patient with chronic sciatic nerve injury[J]. Journal of Neurorestoratology, 2017, 5(1): 1-4.
[14] Alok Sharma, Tongchao Geng, Hemangi Sane, Pooja Kulkarni. Clinical neurorestorative progresses in cerebral palsy[J]. Journal of Neurorestoratology, 2017, 5(1): 51-57.
[15] Yaping Feng, Tiansheng Sun, Lin Chen, Jiaxin Xie, Zhicheng Zhang, Hongyun Huang, Xijing He. Clinical therapeutic guideline for neurorestoration in spinal cord injury (Chinese version 2016)[J]. Journal of Neurorestoratology, 2017, 5(1): 73-83.